XML 58 R44.htm IDEA: XBRL DOCUMENT v2.4.0.8
FAIR VALUE MEASUREMENTS (Details 2) (USD $)
1 Months Ended 9 Months Ended 1 Months Ended 9 Months Ended 9 Months Ended
Dec. 31, 2011
AnnualPayment
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Trius Therapeutics, Inc.
Sep. 30, 2013
Trius Therapeutics, Inc.
Minimum
Sep. 30, 2013
Trius Therapeutics, Inc.
Maximum
Sep. 30, 2013
Trius Therapeutics, Inc.
Weighted Average
Sep. 30, 2013
Adolor
Minimum
Sep. 30, 2013
Adolor
Maximum
Sep. 30, 2013
Adolor
Weighted Average
Sep. 30, 2013
Adolor
Bevenopran (formerly known as CB-5945)
Dec. 31, 2012
Adolor
Bevenopran (formerly known as CB-5945)
Aug. 31, 2013
Calixa Therapeutics Inc.
Sep. 30, 2013
Calixa Therapeutics Inc.
Sep. 30, 2013
Calixa Therapeutics Inc.
Minimum
Sep. 30, 2013
Calixa Therapeutics Inc.
Maximum
Sep. 30, 2013
Calixa Therapeutics Inc.
Weighted Average
Sep. 30, 2013
Calixa Therapeutics Inc.
Ceftolozane/tazobactam (formerly known as CXA-201)
Dec. 31, 2012
Calixa Therapeutics Inc.
Ceftolozane/tazobactam (formerly known as CXA-201)
Sep. 30, 2013
Level 2
2020 Convertible Senior Notes
Sep. 30, 2013
Level 2
2018 Convertible Senior Notes
Sep. 30, 2013
Level 2
2017 Convertible Senior Notes
Sep. 30, 2013
Contingent Consideration
Level 3
Sep. 30, 2013
Contingent Consideration
Level 3
Trius Therapeutics, Inc.
Level 3 Disclosures                                                
Contingent consideration       $ 4,879,000             $ 80,401,000 $ 77,000,000   $ 76,092,000       $ 76,092,000 $ 112,200,000          
Probability of success (as a percent)         4.00% 7.00% 6.00% 29.00% 54.00% 43.00%         29.00% 63.00% 48.00%              
Discount rate (as a percent)       8.00%       5.30% 16.00%         5.30%                    
Contingent Consideration                                                
Undiscounted contingent consideration         0 108,400,000   0 233,800,000         180,000,000                    
Payment for contingent consideration   15,746,000 12,592,000                   40,000,000                      
Reconciliation of fair value using Level 3 inputs, liabilities                                                
Balance at the beginning of the period                                             189,213,000  
Contingent consideration liability recorded upon acquisition                                               4,879,000
Contingent consideration expense                                             7,280,000  
Contingent consideration milestone payment                                             (40,000,000)  
Balance at the end of the period                                             161,372,000  
Other Fair Value Measurements                                                
Fair value of notes                                       480,800,000 379,300,000 526,200,000    
Number of remaining annual payments under termination agreement 6                                              
Aggregate payments due Glaxo 22,500,000                                              
Net carrying amount of the total payable to Glaxo outstanding at the end of the period   $ 14,100,000